Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs

This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs.

Source: Digestive and Liver Disease - January 5, 2021 Category: Gastroenterology Authors: Fabrizio Bossa, Sonia Carparelli, Anna Latiano, Orazio Palmieri, Francesca Tavano, Anna Panza, Maria Pastore, Antonio Marseglia, Mario D'Altilia, Tiziana Latiano, Giuseppe Corritore, Giuseppina Martino, Marianna Nardella, Maria Guerra, Fulvia Terracciano, Tags: Alimentary Tract Source Type: research